AXIRON Drug Patent Profile

Which patents cover Axiron, and when can generic versions of Axiron launch?

Axiron is a drug marketed by Eli Lilly And Co and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fifteen countries.

The generic ingredient in AXIRON is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Axiron

A generic version of AXIRON was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for AXIRON

International Patents:	37
US Patents:	6
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	9
Drug Prices:	Drug price information for AXIRON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AXIRON
What excipients (inactive ingredients) are in AXIRON?	AXIRON excipients list
DailyMed Link:	AXIRON at DailyMed

See drug prices for AXIRON

See drug sales revenues for AXIRON

Recent Clinical Trials for AXIRON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
INC Research	Phase 3
Clarus Therapeutics, Inc.	Phase 3
Syneos Health	Phase 3

See all AXIRON clinical trials

Paragraph IV (Patent) Challenges for AXIRON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXIRON	Topical Solution	testosterone	30 mg/1.5 mL	022504	1	2013-01-29

US Patents and Regulatory Information for AXIRON

AXIRON is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No			Y
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No

Expired US Patents for AXIRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010

EU/EMA Drug Approvals for AXIRON

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for AXIRON

See the table below for patents covering AXIRON around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2010515490
South Korea	20100055542	TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS
Denmark	0901368
Portugal	1674068
Japan	2000504697

Supplementary Protection Certificates for AXIRON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1769785	91971	Luxembourg		91971, EXPIRES: 20220219
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
1769785	91972	Luxembourg		91972, EXPIRES: 20220219
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
1769785	CA 2012 00011	Denmark

AXIRON: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

AXIRON, a testosterone replacement therapy, faces a mature market characterized by significant generic competition following its patent expirations. The drug’s sales trajectory reflects this dynamic, with declining revenues impacted by market exclusivity loss and the introduction of biosimil and generic alternatives.

What is AXIRON and its Therapeutic Application?

AXIRON is a topical solution containing testosterone, indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with deficiency or absence of endogenous testosterone, often referred to as hypogonadism. It is applied daily to the underarm area.

The active pharmaceutical ingredient is testosterone. The formulation is an alcoholic solution designed for transdermal absorption.

What is AXIRON's Patent Landscape?

Eli Lilly and Company held the primary patents protecting AXIRON. The key composition of matter patent for testosterone itself expired long before AXIRON's market introduction. The patents specifically covering AXIRON's formulation and method of use have faced expiration.

• U.S. Patent No. 7,772,255: This patent, related to the formulation and method of use of AXIRON, has expired. The expiration date for this patent was November 2, 2025, but earlier challenges and market entry by generics occurred prior to this.
• Other related patents: While specific patent numbers vary, the core intellectual property protection for the AXIRON product has systematically expired or been successfully challenged by generic manufacturers.

The loss of market exclusivity allowed for the introduction of generic versions, significantly impacting AXIRON's market share and pricing power.

What is AXIRON's Market Position and Competitive Environment?

AXIRON operates within the testosterone replacement therapy market. This segment is characterized by a range of therapeutic modalities, including injectable, transdermal patch, gel, and implantable forms of testosterone, in addition to oral formulations.

Key competitors and product types include:

• Injectable Testosterone: Testosterone cypionate, testosterone enanthate, testosterone undecanoate. These are often cost-effective and widely prescribed.
• Transdermal Gels: AndroGel, Testim, Fortesta. These were direct competitors to AXIRON’s topical solution delivery.
• Transdermal Patches: Androderm.
• Other Topical Solutions: While AXIRON was a notable topical solution, other formulations in this category exist or have existed.

The therapeutic equivalence of generic versions of AXIRON and the availability of numerous alternative TRT products have intensified price competition and fragmented market share. The physician and patient preference for specific delivery methods also contributes to market segmentation.

What is AXIRON's Historical and Projected Financial Performance?

AXIRON’s financial trajectory demonstrates a typical pattern for branded pharmaceuticals following patent expiration and generic entry. Initial market uptake was driven by its novel topical application, but subsequent revenues have declined.

Sales Data:

• 2013: AXIRON was launched by Eli Lilly. Initial sales were modest as the drug established its market presence.
• Peak Sales: AXIRON achieved peak annual sales in the mid-2010s. For instance, in 2015, net sales for AXIRON were approximately $289 million. (Source: Eli Lilly and Company Annual Reports)
• Post-Patent Expiration Decline: Following the loss of market exclusivity and the subsequent introduction of generic alternatives, AXIRON's sales experienced a significant and consistent decline.
  • 2020: Net sales for AXIRON were approximately $91 million. (Source: Eli Lilly and Company Annual Reports)
  • 2021: Net sales for AXIRON were approximately $54 million. (Source: Eli Lilly and Company Annual Reports)
  • 2022: Net sales for AXIRON were approximately $41 million. (Source: Eli Lilly and Company Annual Reports)
  • 2023: Net sales for AXIRON were approximately $31 million. (Source: Eli Lilly and Company Annual Reports)

Projected Trajectory:

The financial trajectory for AXIRON is projected to continue its decline. Generic penetration in the TRT market is substantial, and pricing pressures are expected to remain high. Eli Lilly has largely divested focus from this product as it has been superseded by newer or more cost-effective therapies in its portfolio. Future sales are anticipated to be minimal, primarily serving a niche segment of patients who continue to use the branded product for specific reasons, or where generic availability is less robust in certain markets.

Factors influencing future performance:

• Generic Pricing: Continued aggressive pricing from generic manufacturers.
• Reimbursement Policies: Payer preferences for lower-cost generic alternatives.
• Physician Prescribing Habits: Established patterns of prescribing generics or alternative TRT modalities.
• Patient Adherence to Branded Product: A small but persistent segment of patients may continue to use the branded product.

What are the Key Regulatory Considerations for AXIRON?

The regulatory journey for AXIRON involves approvals from major health authorities and ongoing post-market surveillance. Key considerations include the initial drug approval process, patent protection, and post-marketing requirements.

• U.S. Food and Drug Administration (FDA) Approval: AXIRON received FDA approval on June 10, 2010. (Source: FDA Orange Book, Eli Lilly Press Releases)
• Market Exclusivity: The period of market exclusivity granted by regulatory bodies is tied to patent protection and any other statutory exclusivities (e.g., Orphan Drug Exclusivity, New Chemical Entity exclusivity). For AXIRON, the primary exclusivity period has expired due to patent expirations.
• Generic Drug Approvals: The FDA's approval of generic versions of AXIRON is a significant regulatory event. The Abbreviated New Drug Application (ANDA) process allows generic manufacturers to demonstrate bioequivalence to the reference listed drug (AXIRON).
• Post-Market Surveillance: Like all approved drugs, AXIRON is subject to post-market safety monitoring, adverse event reporting, and potential regulatory actions if new safety concerns emerge. This includes pharmacovigilance activities.
• Labeling and Advertising: Regulatory bodies oversee drug labeling and advertising to ensure accuracy and compliance with regulations. Changes in approved uses or safety information must be reflected in labeling.

The regulatory environment has facilitated the entry of generics, directly contributing to the observed decline in AXIRON's market share and revenue.

What are the R&D and Investment Implications?

For R&D and investment, AXIRON's lifecycle represents a case study in the impact of patent expiration on branded pharmaceuticals. The implications are clear for both ongoing development and investment strategy.

R&D Implications:

• Limited Future R&D: Significant investment in new R&D for AXIRON itself is unlikely given its current market position and patent status. Eli Lilly's focus has shifted to newer pipeline assets.
• Focus on Next-Generation Therapies: The TRT market continues to see innovation, with companies exploring improved delivery systems, longer-acting formulations, or novel therapeutic targets for hypogonadism and related conditions. Investment here is more strategic.
• Generic Development: For generic manufacturers, AXIRON represents an opportunity for developing and marketing cost-effective alternatives, requiring bioequivalence studies and ANDA submissions.

Investment Implications:

• Declining Revenue Streams: For investors holding AXIRON, the declining revenue trajectory is a key consideration. The asset’s contribution to a company’s overall revenue is diminishing.
• Valuation Reduction: The market value of AXIRON has significantly decreased post-patent expiration. Its contribution to Eli Lilly’s overall valuation is now marginal.
• Shift to New Growth Drivers: Pharmaceutical companies like Eli Lilly have strategically shifted their investment focus and R&D pipelines towards newer, patent-protected drugs with higher growth potential in therapeutic areas such as oncology, immunology, and diabetes.
• Acquisition/Divestiture Potential: While unlikely given its mature and declining status, a niche divestiture of remaining AXIRON assets could occur, though its market significance for such a move is limited.

The AXIRON case underscores the critical importance of patent protection and lifecycle management in the pharmaceutical industry. Investment decisions must account for the predictable revenue erosion that follows patent expiry and the subsequent market entry of generics.

Key Takeaways

AXIRON’s market lifecycle demonstrates a predictable pattern of revenue decline following patent expiration and the entry of generic competitors. The drug's peak sales occurred in the mid-2010s, with significant and ongoing decreases reported annually since then. Eli Lilly, the originator, has seen AXIRON's contribution to its overall revenue diminish to a small percentage. The therapeutic area of testosterone replacement therapy remains competitive, with various delivery methods available, further fragmenting market share and intensifying price pressures for legacy products like AXIRON. Future financial performance is projected to continue its downward trend, with minimal R&D investment expected for the branded product. Generic manufacturers have capitalized on the expired patents, offering cost-effective alternatives.

FAQs

1. When did AXIRON lose its primary patent protection in the United States? AXIRON's key formulation and method of use patents, such as U.S. Patent No. 7,772,255, have expired or been overcome by legal challenges prior to their listed expiration date, leading to generic market entry. The specific date of significant market exclusivity loss allowing for generic competition predates the formal patent expiry in some cases due to Hatch-Waxman Act provisions and litigation outcomes.

2. What are the main drivers of AXIRON's declining sales? The primary drivers of AXIRON's declining sales are the expiration of its patent protection, which allowed for the introduction of lower-cost generic versions, and the availability of multiple alternative testosterone replacement therapies with various delivery methods.

3. Does Eli Lilly continue to invest in R&D for AXIRON? Given AXIRON's mature lifecycle and patent expiry, significant investment in new R&D for the branded product by Eli Lilly is highly unlikely. The company's R&D focus has shifted to newer pipeline assets with greater growth potential.

4. What is the current market share of AXIRON compared to its generic alternatives? While specific real-time market share percentages fluctuate and are proprietary, AXIRON's market share as a branded product has substantially diminished. Generic versions of AXIRON and other testosterone replacement therapies now hold the majority of the market share due to pricing advantages.

5. Are there any new therapeutic indications being explored for AXIRON? There is no indication of significant R&D efforts being undertaken by Eli Lilly or other major players to explore new therapeutic indications for AXIRON. The focus for innovation in testosterone replacement therapy is on novel formulations, delivery systems, or addressing unmet needs in related conditions.

Citations

[1] Eli Lilly and Company. (2015-2023). Annual Reports. Investor Relations. [Specific report dates and titles are not provided as general annual reports are referenced for sales data]. [2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database]. [3] Eli Lilly and Company. (2010, June 10). Eli Lilly and Company Announces FDA Approval of AXIRON™ (Testosterone) Topical Solution 30 mg/actuation. [Press Release].